Abstract
Photodynamic therapy (PDT) is used in Europe to treat basal cell carcinoma (BCC), but it is not approved in the USA due to uncertainties about efficacy. Vitamin D3 (VD3; cholecalciferol) treatment prior to PDT improves BCC responses in mice. A prospective, double-blind, crossover clinical trial [NCT03467789] was designed to test whether oral VD3 pretreatment enhances BCC response to blue light PDT. Participants received 3 PDT treatments (20% ALA, 4 h; 417 nm, 30 min) 2 months apart. High-dose VD3 or placebo was administered prior to each of the first two PDT sessions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
